New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 1, 2010, Pages 46-57

  Duque, María D ^a   Camps, Pelayo ^a   Torres, Eva ^a   Valverde, Elena ^a   Sureda, Francesc X ^b   López Querol, Marta ^b   Camins, Antoni ^a   Prathalingam, S Radhika ^c   Kelly, John M ^c   Vázquez, Santiago ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Amantadine; Indantadol; Memantine; NGP1 01; NMDA; Polycyclic cage compounds; Trypanosoma

Indexed keywords

( 5 ETHYL 1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)AMINE; (1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)AMINE; (1,2,3,5,6,7 HEXAHYDRO 5 METHYL 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)AMINE; 1,2,3,5,6,7 HEXAHYDRO 5 METHYL 1,5:3,7 DIMETHANO 4 BENZO XONIN 3 OL; 2 [(1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO BENZOXONIN 3 YL)AMINO]ACETAMIDE; 5 ETHYL 1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 OL; ANTITRYPANOSOMAL AGENT; MEMANTINE; N ( 5 ETHYL 1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)ACETAMIDE; N (1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)ACETAMIDE; N (1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)PIPERIDINE; N (1,2,3,5,6,7 HEXAHYDRO 5 METHYL 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)ACETAMIDE; N (2 PHENYLETHYL) (1,2,3,5,6,7 HEXAHYDRO 1,5:3,7DIMETHANO 4 BENZOXONIN 3 YL)AMINE; N BENZYL ( 5 ETHYL 1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETH ANO 4 BENZOXONIN 3 YL)AMINE; N BENZYL (1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3YL)AMINE; N BENZYL N METHYL (1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)AMINE; N METHYL (1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)AMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N PROPARGYL (1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)AMINE; N PROPARGYL (5 ETHYL 1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)AMINE; N,N DIBENZYL (1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)AMINE; N,N DIETHYL (1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)AMINE TARTRATE; N,N DIMETHYL (1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)AMINE; N,N DIMETHYL (1,2,3,5,6,7 HEXAHYDRO 5 METHYL 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)AMINE; N,N DIMETHYL (1,2,3,5,6,7 HEXAHYDRO 5 METHYL 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)AMINE TARTRATE; N,N DIPROPARGYL ( 5 ETHYL 1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHA NO 4 BENZOXONIN 3 YL)AMINE; N,N DIPROPARGYL (1,2,3,5,6,7 HEXAHYDRO 1,5:3,7 DIMETHANO 4 BENZOXONIN 3 YL)AMINE; RIMANTADINE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PROTON TRANSPORT; TRYPANOSOMA BRUCEI;

TRYPANOSOMA;

EID: 72149107359     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.11.017     Document Type: Article

References (47)

1. Lees A.J., Hardy J., and Revesz T. Lancet 373 (2009) 2055
2. Jakob-Roetne R., and Jacobsen H. Angew. Chem., Int. Ed. 48 (2009) 3030
3. Duara R., Barker W., Loewenstein D., and Bain L. Alzheimers Dement. 5 (2009) 66
4. Stone T.W., and Addae J.I. Eur. J. Pharmacol. 447 (2002) 285
5. Hynd M.R., Scott H.L., and Dodd P.R. Neurochem. Int. 55 (2004) 583
6. Raina P., Santaguida P., Ismaila A., Patterson C., Cowan D., Levine M., Booker L., and Oremus M. Ann. Intern. Med. 148 (2008) 379
7. Parsons C.G., Danysz W., and Quack G. Neuropharmacology 38 (1999) 735
8. Lipton S.A. Nat. Rev. Drug Disc. 5 (2006) 160
9. Rammes G., Danysz W., and Parsons C.G. Curr. Neuropharmacol. 6 (2008) 55
10. Gilling K.E., Jatzke C., Hechenberger M., and Parsons C.G. Neuropharmacology 56 (2009) 866
11. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., and Quack G. Neurosci. Biobehav. Rev. 21 (1997) 455
12. De Clercq E. Nat. Rev. Drug Disc. 5 (2006) 1015
13. Kelly J.M., Miles M.A., and Skinner A.C. Antimicrob. Agents Chemother. 43 (1999) 985
14. Kelly J.M., Quack G., and Miles M.A. Antimicrob. Agents Chemother. 45 (2001) 1360
15. Kolocouris N., Zoidis G., Foscolos G.B., Fytas G., Prathalingam S.R., Kelly J.M., Naesens L., and De Clercq. Bioorg. Med. Chem. Lett. 17 (2007) 4358
16. Papanastasiou I., Tsotinis A., Kolocouris N., Prathalingam S.R., and Kelly J.M. J. Med. Chem. 51 (2008) 1496
17. Geldenhuys W.J., Malan S.F., Bloomquist J.R., Marchand A.P., and van der Schyf C.J. Med. Res. Rev. 25 (2005) 21
18. Oliver D.W., and Malan S.F. Med. Chem. Res. 17 (2008) 137
19. van der Schyf C.J., and Geldenhuys W.J. Neurotherapeutics 6 (2009) 175
20. Oliver D.W., Dekker T.G., and Snyckers F.O. Arzneim.-Forsch./Drug Res. 41 (1991) 549
21. Oliver D.W., Dekker T.G., Snyckers F.O., and Fourie T.G. J. Med. Chem. 34 (1991) 851
22. Zhou J.J.P., Li J., Upadhyaya S., Eaton P.E., and Silverman R.B. J. Med. Chem. 40 (1997) 1165
23. Geldenhuys W.J., Terre'Blanche G., van der Schyf C.J., and Malan S.F. Eur. J. Pharmacol. 458 (2003) 73
24. Geldenhuys W.J., Malan S.F., Murugesan T., van der Schyf C.J., and Bloomquist J.R. Bioorg. Med. Chem. 12 (2004) 1799
25. Mdzinarishvili A., Geldenhuys W.J., Abbruscato T.J., Bickel U., Klein J., and van der Schyf C.J. Neurosci. Lett. 383 (2005) 49
26. Grobler E., Grobler A., van der Schyf C.J., and Malan S.F. Bioorg. Med. Chem. 14 (2006) 1176
27. Kiewert C., Hartmann J., Stoll J., Thekkumkara T.J., Geldenhuys W.J., and Klein J. Neurochem. Res. 31 (2006) 395
28. Geldenhuys W.J., Malan S.F., Bloomquist J.R., and van der Schyf C.J. Bioorg. Med. Chem. 15 (2007) 1525
29. Hao J., Mdzinarishvili A., Abbruscato T.J., Klein J., Geldenhuys W.J., van der Schyf C.J., and Bickel U. Brain Res. 1196 (2008) 113
30. van Dijk A., Johnston C., Allbutt H., Kassiou M., and Henderson J. Behav. Brain Res. 190 (2008) 14
31. Liu X., Banister S.D., Christie M.J., Banati R., Meikle S., Coster M.J., and Kassiou M. Eur. J. Pharmacol. 555 (2007) 37
32. Liu X., Kassiou M., Christie M.J., and Hambley T.W. Aust. J. Chem. 54 (2001) 31
33. Duque M.D., Camps P., Profire L., Montaner S., Vázquez S., Sureda F.S., Mallol J., López-Querol M., Naesens L., De Clercq E., Prathalingam S.R., and Kelly J.M. Bioorg. Med. Chem. 17 (2009) 3198
34. Föhlisch B., Dukek U., Graeβle I., Novotny B., Schupp E., Schwaiger G., and Widmann E. Liebigs Ann. Chem. (1973) 1839
35. Bishop R. Aust. J. Chem. 37 (1984) 319
36. Camps P., Görbig D., Muñoz-Torrero V., and Pérez F. Collect. Czech. Chem. Commun. 62 (1997) 1585
37. Mattia C., and Coluzzi F. Drugs 10 (2007) 636
38. Planells-Cases R., Montoliu C., Humet M., Fernández A.M., García-Martinez C., Valera E., Merino J.M., Pérez-Payá E., Messeguer A., Felipo V., and Ferrer-Montiel A. J. Pharmacol. Exp. Ther. 302 (2002) 163
39. Sánchez-Pérez A.M., Montoliu C., and Felipo V.C.N.S. Drug Rev. 9 (2003) 263
40. Shokova E., Mousoulou T., Luzikov Y., and Kovalev V. Synthesis (1997) 1034
41. Lipton S.A. Nat. Rev. Drug Disc. 5 (2006) 160
42. Greenamyre J.T., and O'Brien C.F. Arch. Neurol. 48 (1991) 977
43. Camps P., Duque M.D., Vázquez S., Naesens L., De Clercq E., Sureda F.S., López-Querol M., Camins A., Pallàs M., Prathalingam S.R., Kelly J.M., Romero V., Ivorra D., and Cortés D. Bioorg. Med. Chem. 16 (2008) 9925
44. Oldfield V., Keating G.M., and Perry C.M. Drugs 67 (2007) 1725
45. LeWitt P.A. Neurology 72 (2009) 1352
46. Tipton K.F. Eur. J. Biochem. 4 (1968) 103
47. Hirumi H., and Hirumi K. J. Parasitol. 75 (1989) 985